Recent clinical guidance for people on GLP-1s suggests this range helps preserve muscle during weight loss
So, in 2014, liraglutide was approved for weight loss (as Saxenda), causing average decreases in body mass of about 8%
This approach might provide a more informative evaluation of the efficacy of a new therapy by addressing potential confounding factors arising from imbalanced baseline features ( Skewed distributions associated with L-carnitine non-effective patients posed challenges for mean and standard deviation in accurately depicting data tendencies and variability
The combination of spironolactone and metformin is also highly effective
Less common but noteworthy side effects include fatigue , dizziness, headaches , and abdominal pain
The authors hope that this review will contribute to a better understanding of the role and relevance of GLP-1 RAs in the treatment of T2D.